The percutaneous coronary intervention market size is projected to reach USD 23.2 Billion by 2030 and anticipated to grow at a compound annual growth rate of 5.1% through 2022-2030. Treatment is known as percutaneous coronary intervention, or PCI is used to treat coronary artery disease by opening up narrowed arteries. Heart vessels that have been restricted by plaque buildup may be opened with the use of this surgery, which involves the use of a catheter to insert an implant.
Recent years have seen an increase in heart disease as one of the top causes of mortality for both men and women. Acute heart attacks, angina, heart attacks, and heart problems may all be helped by PCI, which is a procedure that uses small incisions in the arteries that provide blood to the heart. Cardiovascular disease is becoming more and more common, and as a result, PCI has become more important in the last several years. An estimated 3.9 million Europeans die each year from cardiovascular disease, with the EU-wide death toll exceeding 1.8 million. In particular, cardiovascular disease is responsible for around 45 percent of all fatalities in Europe and 37 percent of all deaths in the EU. Having many such people with renal illness has promoted the industry's growth over several years.
This report contains all the information on the global percutaneous coronary intervention market analysis and the market strengths. In addition, the report also includes the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global percutaneous coronary intervention market forecast for 2030 is also included in the report.
Covid 19 Analysis
It was anticipated that these markets would expand at a Compound Annual Growth Rate of around 5percent over the next 10 years before the breakout of the Covid-19 virus. While the pandemic is predicted to influence the development of various MedTech industries, the cardiology demand is anticipated to be less affected than the others. Due to their elevated risk of contracting Covid-19 and the time-sensitive nature of their medications, people with cardiovascular conditions need ongoing care.
Percutaneous Coronary Intervention Market Dynamic
The expanding senior population, which is more prone to heart illness, the increasing incidence of cardiac disorders, and the increasing desire for minimally invasive treatments are all expected to expand this percutaneous coronary intervention market growth.
Additionally, the adoption of technological improvements within the percutaneous coronary intervention, like sophisticated silicone and polymer implants in growing countries such as China, Brazil, and India, presents chances for the market's development throughout the projection period.
Nevertheless, the strict rules imposed by the government about the process can be a barrier to the expansion of the percutaneous coronary intervention market value.
Nevertheless, the market's expansion will be slowed if reimbursement policies in undeveloped countries are unjust and unfair. There may also be problems for the industry due to the high expenses of robotically assisted surgery. The backward countries' lack of access to qualified specialists is another factor that would slow the pace of market expansion.
Percutaneous Coronary Intervention Market Cumulative Growth Analysis
Chinese coronary heart disease is the 2nd biggest cause of cardiovascular fatalities, contributing to 23% of urban deaths and 14% of country deaths. CVD is responsible for 41% of China's annual mortality toll, over 3 million people.
Ischemia of the heart affects over 2.4 million Canadians over 20. In 2012, heart disease was the second leading cause of death in Canada, taking the lives of more than 48500 people. CVD also claims the life of one Canadian every seven minutes. In Europe, cardiovascular disease is responsible for over half of all fatalities. When AIDS, tb, and malaria are taken into account, the disease burden of cardiovascular disease in Europe is greater. Hypertension, obesity, alcohol and cigarette use are all factors that lead to an increased incidence of CAD disorders. As the prevalence of coronary heart disease rises, so does the use of percutaneous coronary intervention devices, boosting the global market for these devices.
Percutaneous Coronary Intervention Market Value Chain Analysis
According to the product type, the worldwide percutaneous coronary intervention market has now been split up into the following categories: coronary stents, coronary guidewires, PTCA catheters, and accessories. The market for percutaneous coronary intervention has indeed been segmented into hospitals and treatment centers, ambulatory surgery centers, study and academic institutions, and other organizations based on the kind of end-user they serve.
There are four main categories of products in the worldwide percutaneous coronary intervention industry: catheters, stents, guidewires, and accessories.
Percutaneous Coronary Intervention Market Segmentation Overview
The market is segmented based on: coronary stents, coronary guidewires, PTCA catheters, accessories and geography. As a result, the global percutaneous coronary intervention market trends are expected to witness decent growth during the forecast period.
By Product Type
The market is segmented into Coronary Stents, PTCA Catheters, Coronary Guidewire, and Accessories.
The market is segmented into hospitals and treatment centers, ambulatory surgery centers, study and academic institutions, and other organizations based on propulsion types.
The worldwide market for percutaneous coronary intervention has been segmented into the following four areas: the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
It is predicted that the Americas will account for most worldwide percutaneous coronary interventions. Percutaneous coronary intervention (PCI) is becoming more popular in the United States and Canada, and that region is projected to take the lead in the next years. Over the projection period, Europe is predicted to have the second-largest market share. Percutaneous coronary intervention procedures, like carotid artery angioplasty and cerebral angioplasty, are driving market expansion in this area.
In the worldwide market, Asia-Pacific is expected to expand at the quickest rate due to the growing incidence of cardiovascular illnesses and improved healthcare facilities and rising income levels. It is projected that the Middle East & Africa percutaneous coronary intervention market share will increase owing to the high frequency of the procedure in Kuwait, Saudi Arabia, and the UAE.
Percutaneous Coronary Intervention Market Competitive landscape
In the worldwide market for percutaneous coronary intervention, the most important tactics that market participants used were innovation, the creation of new products, and acquisitions and mergers.
Major Key Players
The following report comprises of –
Percutaneous Coronary Intervention Market, by Product Type
Percutaneous Coronary Intervention Market, by End User
Percutaneous Coronary Intervention Market, by Region
Rest of Western Europe
Middle East & Africa
|Market Size||USD 23.2 Billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product Type, End User and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (US), ASAHI INTECC Company Limited (Japan), B. Braun Melsungen AG (UK), Biosensors International Group, Ltd (Singapore), BIOTRONIK (US), Boston Scientific Corporation (US), C. R. Bard, Inc. (US), Comed BV (Netherlands), Cook (US), Cordis (US), Medtronic PLC (US), Meril Lifesciences Pvt. Ltd (India), Merit Medical System ( Utah), and Terumo Corporation ( Japan)|
|Key Market Opportunities||Favorable Reimbursement Scenario|
|Key Market Drivers||
Percutaneous coronary intervention market projected to grow at approximately 5.1% CAGR during the assessment period (2022-2030).
The valuation of the global percutaneous coronary intervention market is estimated to increase to USD 23.2 BN by the end of 2030.
In addition to the rising prevalence of chronic heart diseases, the increasing adoption of PCI procedures performed on patients with coronary artery disease and rising funding for R&D & clinical trials are major tailwinds pushing the growth of the global percutaneous coronary intervention market.
North America holds the largest share in the global percutaneous coronary intervention market, followed by Europe and the Asia Pacific, respectively.
Abbott (U.S.), Boston Scientific Corporation (U.S.), ASAHI INTECC Company Limited (Japan), Cordis (U.S.), Cook Medical (U.S.), Comed B.V. (The Netherlands), C. R. Bard, Inc. (U.S.), Biosensors International Group, Ltd. (Singapore), Meril Lifesciences Pvt Ltd. (India), Terumo Corporation (Japan), Medtronic Plc. (U.S.), B BIOTRONIK (U.S.), Braun Melsungen AG (Germany), and Merit Medical System (U.S.), are some of the top players operating in the global percutaneous coronary intervention market.
Global Percutaneous Coronary Intervention Market: Company Landscape
The Global Percutaneous Coronary Intervention Market is dominated by several market players such as Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cook Medical, Medtronic Plc, and others. Major players in the percutaneous coronary intervention market are opting for strategic collaborations and partnerships, and new product launches to brace their position in the market.
Abbott accounted for the largest share in the global percutaneous coronary intervention market in the year 2017. The company employs a strategy of focusing on severe diseases, maintaining the quality of products by maximum automation and rising investment in research and development which helps the company in maintaining its market position. Additionally, the company is engaged in new product launches and strategic partnerships. For instance, in October 2017, Abbott announced an updated version of everolimus-eluting, metallic stent Xience with a new stent design, a new delivery system, and unique sizes. Also, in January 2017, the company announced that it had completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena.
Boston Scientific Corporation held a prominent share in the year 2017. The company works collaboratively to resolve the toughest problems of healthcare industries by developing solutions for patients suffering from life-threatening circumstances. The company focuses on developing high-quality products by using less invasive techniques. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage. In October 2015, the company received the Food and Drug Administration (FDA) approval for SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System for the treatment of coronary artery disease. With this approval, the company gained the rights to market the product in the US.
Medtronic is also a renowned player in the global percutaneous coronary intervention market. With the acquisition of Covidien, Medtronic has augmented its ability to create meaningful innovations for hospitals and healthcare providers so that it can deliver the best care possible to patients around the world. The company focuses on new product launches for the expansion of its product portfolio. For instance, in February 2018, Medtronic launched the first 2.0 mm Drug-Eluting stent Resolute Onyx in the US. The new product is intended to help interventional cardiologists treat patients with coronary artery disease (CAD) who have small vessels.
Terumo Medical Corporation is one of the major companies in the market. The company has successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. By doing this, the company aims at strengthening its position in the market. For instance, in July 2018, the company acquired China-based Essen Technology to enter the drug-eluting stent market in China.
Cordis is one of the key companies having unmatched offerings in cardiology devices. The company was acquired by Cardinal Health in October 2015. The company focuses on strategic partnerships and new innovative product launches for its expansion in the market. For instance, in October 2016, the company announced several new strategic distribution agreements in the interventional vascular business for the expansion of its product portfolio in selected countries. Also, in November 2017, Cordis and Medinol announced the US Food and Drug Administration (FDA) approval of the EluNIR drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries.
Other companies in the percutaneous coronary intervention market are Cook Medical, C. R. Bard, Inc., Comed B.V., and Meril Lifesciences Pvt. Ltd, among others.